Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. (CDNA) operates at the forefront of transplant medicine, where product innovations, clinical trial results, and regulatory developments drive significant news flow. As a precision diagnostics company focused on organ transplantation, CareDx generates news related to clinical study publications, FDA and regulatory interactions, reimbursement policy changes, and product commercialization milestones. This news page provides comprehensive coverage of developments affecting the company's transplant surveillance and HLA typing businesses.
The types of news that matter most for CareDx include peer-reviewed study publications demonstrating clinical utility of its dd-cfDNA technology, Medicare coverage determinations that impact reimbursement for surveillance testing, product launches expanding into new transplant types or international markets, and earnings reports revealing testing volume trends. Additionally, significant 8-K filings may disclose material events such as partnership agreements with transplant centers, changes in reimbursement policies, or intellectual property developments. Understanding these news categories helps investors track the company's progress in validating its technology platform and expanding commercial adoption.
CareDx's news flow reflects the biotech and diagnostics industry's focus on evidence generation and regulatory milestones. Clinical data presentations at major transplant medicine conferences like the American Transplant Congress and American Society of Nephrology provide insights into product performance and physician adoption trends. Regulatory submissions for expanded product indications, international certifications, and coverage policy updates from insurers represent critical catalysts that can accelerate or constrain market penetration for the company's diagnostic services.
CareDx, Inc. (NASDAQ: CDNA), known as The Transplant Company™, announced its participation in the Raymond James & Associates’ 44th Annual Institutional Investors Conference. The presentation is scheduled for Monday, March 6, 2023, at 4:35 PM ET. Investors can access the webcast by visiting CareDx's investor relations page at investors.caredxinc.com. CareDx is a leader in precision medicine solutions, offering innovative testing services and digital healthcare solutions for transplant patients throughout their journey.
CareDx, Inc. (NASDAQ: CDNA) announced the release of a Billing Article regarding MolDX Molecular Testing for Solid Organ Allograft Rejection, effective March 31, 2023. CEO Reg Seeto clarified that MolDX will not modify the foundational LCD but issued this article for clarification. Key points include reimbursement coverage for testing services, standalone billing for AlloSure Heart, which can now be billed separately from AlloMap Heart, and a pathway for multimodality testing with additional data. CareDx plans to engage further with MolDX and update their HeartCare submission and procedures accordingly.
CareDx, Inc. (NASDAQ: CDNA) has announced its eighth consecutive sponsorship of the National Kidney Foundation's Annual Kidney Patient Summit, scheduled for March 1-2, 2023, on Capitol Hill. This event aims to raise awareness about kidney disease during National Kidney Month. CareDx aims to enhance patient care and promote early detection of chronic kidney disease. The company invests in transplant innovations, supporting various legislative policies, including the Living Donor Protection Act. CEO Reg Seeto emphasized their commitment to improving the patient journey from early interventions to post-transplant monitoring.
CareDx, Inc. (Nasdaq: CDNA) reported its financial results for Q4 and the full year 2022. The company achieved full-year revenue of $321.8 million, a 9% increase from 2021, with Q4 revenue hitting $82.4 million, up 4% year-over-year. Testing volumes for AlloMap and AlloSure grew by 19% to approximately 182,000 tests for 2022. However, the net loss increased to $76.6 million for the year, from $30.7 million in 2021. Cash and equivalents stand at $293 million. For 2023, CareDx anticipates revenue between $328 million and $338 million.
CareDx, Inc. (NASDAQ: CDNA) announced its participation in the American Society of Transplantation Cutting Edge of Transplantation (CEoT) meeting in Scottsdale, Arizona, from February 23-25. The company will showcase advancements in molecular diagnostics and artificial intelligence aimed at improving the health of transplant patients. A symposium titled 'Elevating Transplant Care by Combining Molecular Diagnostics and Artificial Intelligence' is scheduled for February 24, featuring a panel of leading experts in transplantation. CareDx emphasizes its commitment to innovation and enhancing long-term allograft health.
CareDx, Inc. (NASDAQ: CDNA) has announced it will report its financial results for the fourth quarter and full year 2022 on February 27, 2023, after market closure. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET for management to discuss the results. Interested parties can join the call by dialing 1-877-704-4453 (domestic) or 1-201-389-0920 (international), referencing Conference ID: 13736063. CareDx specializes in precision medicine solutions for transplant patients, delivering testing services and products throughout the patient journey.
CareDx, Inc. (CDNA) announced the publication of a guide in the Journal of the American College of Cardiology to assist clinicians in transitioning from invasive endomyocardial biopsies (EMB) to non-invasive monitoring for heart transplant rejection using AlloMap GEP and AlloSure dd-cfDNA. The guide highlights the clinical utility of these non-invasive tests, emphasizing their effectiveness in rejection surveillance. CareDx's HeartCare services are now utilized in over 90% of U.S. heart transplant centers, reflecting a growing trend towards non-invasive practices in heart transplant monitoring.
CareDx (NASDAQ: CDNA) announced its participation as a Distinguished Founder’s Circle Sponsor at the 23rd Annual ASTS State of the Art Winter Symposium from January 12-15, 2023, in Miami, Florida. This marks the fourth consecutive year for CareDx at this event, emphasizing their commitment to innovation in transplant patient care. The company will host a symposium on January 13 to present advancements in molecular surveillance and digital health solutions. CareDx’s products, like AlloMap and AlloSure, are widely used in transplant centers across the U.S.
CareDx, Inc. (NASDAQ: CDNA) reported preliminary financial results for Q4 and full year 2022, highlighting record revenues between $81.9 million and $82.2 million, marking a 4% year-over-year growth. Cash collections reached 110% of revenue, a 10% increase, while patient test results rose by 14%. The company maintained a strong cash position of approximately $292 million with no debt. For FY 2022, revenue is expected to be between $321.3 million and $321.6 million, indicating an 8% growth. CareDx plans to focus on pipeline catalysts and increased collections in 2023.
FAQ
What is the current stock price of Caredx (CDNA)?
What is the market cap of Caredx (CDNA)?
